Greenwich LifeSciences, Inc.
GLSIDrugs in Pipeline
34
Phase 3 Programs
20
Upcoming Catalysts
2
Next Catalyst
Aug 13, 2026
10dMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
GLSI Earnings Report
EPS Est: $-0.33 | FQ end 2026-06
1 more catalyst beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How GLSI's past catalysts played out
GLSI-100
Breast Cancer
Human immunoglobulin intravenous
Immune Thrombocytopenia
GC3110A(Quadrivalent)
Influenza
GC1107
Bacterial Infections
GC5107
Immunologic Deficiency Syndromes
Varicella Vaccine
Healthy Children
MG1109
Influenza
GC3107
BCG Vaccination Reaction
GreenGene
Hemophilia A
Hantavax injection
Infection
GCPGC 3.6mg
Chemotherapy Induced Neutropenia
Shinbaro Capsule
Osteoarthritis
Immune Globulin Intravenous (Human) 5% Liquid, IVIG-SN™
Immunologic Deficiency Syndrome
GC3110A vaccine
Influenza, Human
LAENNEC (Human Placenta Hydrolysate) IV
Chronic Liver Disease
GC3110A
Influenza
GC3102C
Prophylaxis Against Influenza
Adjuvanted influenza A(H1N1) vaccine
Influenza Infection
Hunterase
Hunter Syndrome
Tetanus and Diphtheria(Td vaccine)
Bacterial Infections
GC1102 50,000 IU
Hepatitis B Infection
CBD
Diabetic Neuropathies
GC3114
Influenza, Human
Immunoglobulin G
Autoimmune Encephalitis
Quadrivalent influenza vaccine
Influenza
LAENNEC (Human Placenta Hydrolysate)
Chronic Liver Disease
GHB16L2
Influenza, Human
Step 1
Influenza
GC1111_0.5mg/kg
Mucopolysaccharidosis II
GHB11L1
Influenza, Human
irinotecan
Metastatic Colorectal Cancer
MG1111 (BARICELA)
Varicella
Quadrivalent cell-culture based influenza vaccin
Influenza
GC5131
Covid19
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
GLSI-100 | Phase 3 | Breast Cancer | - | - |
Human immunoglobulin intravenous | Phase 3 | Immune Thrombocytopenia | - | - |
GC3110A(Quadrivalent) | Phase 3 | Influenza | - | - |
GC1107 | Phase 3 | Bacterial Infections | - | - |
GC5107 | Phase 3 | Immunologic Deficiency Syndromes | - | - |
Varicella Vaccine | Phase 3 | Healthy Children | - | - |
MG1109 | Phase 3 | Influenza | - | - |
GC3107 | Phase 3 | BCG Vaccination Reaction | - | - |
GreenGene | Phase 3 | Hemophilia A | - | - |
Hantavax injection | Phase 3 | Infection | - | - |
GCPGC 3.6mg | Phase 3 | Chemotherapy Induced Neutropenia | - | - |
Shinbaro Capsule | Phase 3 | Osteoarthritis | - | - |
Immune Globulin Intravenous (Human) 5% Liquid, IVIG-SN™ | Phase 3 | Immunologic Deficiency Syndrome | - | - |
GC3110A vaccine | Phase 3 | Influenza, Human | - | - |
LAENNEC (Human Placenta Hydrolysate) IV | Phase 3 | Chronic Liver Disease | - | - |
GC3110A | Phase 3 | Influenza | - | - |
GC3102C | Phase 3 | Prophylaxis Against Influenza | - | - |
Adjuvanted influenza A(H1N1) vaccine | Phase 3 | Influenza Infection | - | - |
Hunterase | Phase 3 | Hunter Syndrome | - | - |
Tetanus and Diphtheria(Td vaccine) | Phase 3 | Bacterial Infections | - | - |
GC1102 50,000 IU | Phase 2 | Hepatitis B Infection | - | - |
CBD | Phase 2 | Diabetic Neuropathies | - | - |
GC3114 | Phase 2 | Influenza, Human | - | - |
Immunoglobulin G | Phase 2 | Autoimmune Encephalitis | - | - |
Quadrivalent influenza vaccine | Phase 2 | Influenza | - | - |
LAENNEC (Human Placenta Hydrolysate) | Phase 2 | Chronic Liver Disease | - | - |
GHB16L2 | Phase 2 | Influenza, Human | - | - |
Step 1 | Phase 2 | Influenza | - | - |
GC1111_0.5mg/kg | Phase 2 | Mucopolysaccharidosis II | - | - |
GHB11L1 | Phase 2 | Influenza, Human | - | - |
irinotecan | Phase 2 | Metastatic Colorectal Cancer | - | - |
MG1111 (BARICELA) | Phase 2 | Varicella | - | - |
Quadrivalent cell-culture based influenza vaccin | Phase 2 | Influenza | - | - |
GC5131 | Phase 2 | Covid19 | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Greenwich LifeSciences, Inc.'s drug pipeline?→
CatalystAlert tracks 34 drug candidates in Greenwich LifeSciences, Inc.'s (GLSI) pipeline across Phase 3, Phase 2. Its lead program is GLSI-100 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Greenwich LifeSciences, Inc.'s next FDA catalyst?→
Greenwich LifeSciences, Inc.'s (GLSI) next tracked catalyst is a Earnings expected August 13, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track GLSI biotech catalysts?→
Add GLSI to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Greenwich LifeSciences, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.